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Towards better control of the cattle-killing 
disease East Coast fever  
 
Concerted effort over 50 years by a large multi-disciplinary 
and multi-national team has successfully developed a vaccine 
that could prevent one million cattle deaths and save Africa’s 
cattle keepers over US$ 300 million a year. Meanwhile, on-
going research aims to take advantage of cutting-edge science 
to develop an improved vaccine that will be cheaper, safer 
and more convenient to use - overcoming the major 
drawbacks of the rather crude, though effective first vaccine.  
 
What is East Coast fever? 
East Coast fever (ECF) is a devastating disease of cattle 
caused by a single-celled parasite known to science as 
Theileria parva, and carried by ticks feeding on the cattle. The 
disease occurs in 11 countries in east, central and southern 
Africa where the brown-ear tick, which spreads the disease, is 
found.  
 
ECF kills at least and probably more than one million cattle 
each year and affects both improved types of dairy cattle and 
African zebu cattle. It is widely regarded as being amongst the 
most serious constraints to increasing the productivity of dairy 
and beef cattle in the region. In 2005, an ILRI-led study 
estimated that ECF caused annual economic losses totalling 
more than US$ 300 million: more than 45 million of the 
region’s 75 million cattle are at risk of ECF.  The disease also 
hinders the widespread use of more productive, but also 
more susceptible, European cattle breeds. 
 
For the past century ECF has been partially controlled by 
limiting tick infestation by use of chemical sprays, dips and, 
more recently, oil-based pour-ons. This approach has a 
number of disadvantages including development of pesticide 
resistance in the tick population, while few if any new 
chemical products are expected to be released on the 
market. Another disadvantage is the exposure of farmers to 
potential health risks, which are exacerbated by lack of 
protective clothing amongst the poor. Environmental 
contamination is another disadvantage arising from the 
frequent use of pesticides – in high-risk ECF areas application 
might be needed every five or so days.  
 
Some drugs are available for treatment of ECF.  To be 
effective, they need to be used at an early stage of the 
disease. However, the cost per animal is relatively high, 
making this less affordable for the owners of African zebu 
cattle, which are less productive.  
 
It was with this background that a form of vaccination, known 
as the ECF Infection and Treatment Method (ECF ITM) was 
developed. 
 
What is the ECF infection and 
treatment method? 
The ECF ITM is an immunisation procedure involving 
inoculation of cattle with live ECF parasites combined with 
simultaneous treatment with an antibiotic. Without this 
treatment the parasites would kill the cattle, but the antibiotic 
suppresses the infection. The result is a mild ECF reaction 
followed by life-long immunity to the disease.  
 
Although rather crude – differing little from the first-ever live 
vaccine developed by Edward Jenner more than 200 years 
ago - the ECF ITM vaccine is effective if appropriate care is 
taken in its manufacture, storage and use. 
However, the vaccine has disadvantages.  One important one 
is that the live parasites used for the vaccine have to be 
stored at very low temperatures. This is achieved by keeping 
them in liquid nitrogen, but maintaining supplies of this ultra-
low temperature liquid in remote parts of Africa is logistically 
challenging.   
Another problem is that a small number of animals might 
react to the vaccination and get clinical disease, especially if 
proper care is not taken to give the correct amount of the 
antibiotic. 
Calves as young as one month of age can be vaccinated. A 
low dose of laboratory-prepared live parasites is thawed out 
and injected under the skin close to the ear (to mimic natural 
feeding by the brown ear tick), while the antibiotic is injected 
into the muscle. Vaccinated cattle are fitted with a unique 
numbered and colour-coded ear tag, which shows they have 
received the vaccine and also identifies the supplier of the 
vaccine. Vaccinated animals develop immunity to ECF that will 
last all of their lives. 
 
ILRI’s role in the ITM vaccine 
Work to develop an ECF vaccine began at the East African 
Veterinary Research Organisation, Muguga, Kenya in the 
1960s and was continued at the National Veterinary Research 
Centre in Kenya. This culminated in the introduction of a 
version of the ECF ITM vaccine, known as the ‘Muguga 
cocktail’, on a commercial basis in various eastern African 
countries for various classes of cattle between 1998 (Tanzania 
pastoral sector) and 2012 (Kenya dairy sector), using vaccine 
produced by ILRI.  
 
For close to 50 years, many partners have been involved in 
the testing, refinement, re-testing, production, registration and 
commercialisation of the vaccine, enabled by financial support 
over more than four decades provided by a large number of 
donors. 
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ILRI has and continues to work with this wide range of 
partners playing various roles. This collaborative work has had 
a significant impact on the development and refinement of 
the ECF ITM approach, helping to ensure continuous supply 
of quality-assured vaccine at critical times and providing the 
answers to some key questions. ILRI’s contributions fall into 
three main categories: 
 
 Development and application of molecular tools - 
critical to production of quality-assured vaccine and 
to tracking performance of the vaccine in the field. 
 Ensuring continued supply of quality-assured vaccine 
– stepping in to demonstrate the feasibility of 
manufacture of the Muguga cocktail at a commercial 
level when no other organization was able and 
willing to do so, and capacity-building and supporting 
a Malawi-based lab to take over long-term 
production. 
 On-going technical support and backstopping as 
needed. 
Together these contributions have enabled the ECF ITM 
vaccine to be used to immunise hundreds of thousands of 
cattle in both the extensive (pastoralist and ranch) and dairy 
sectors. They have also helped pave the way for commercial 
production, distribution and large-scale deployment of the 
vaccine throughout the region.  
 
Impact of the vaccine 
The impact of the ECF ITM vaccine has been considerable. 
For example, in one pastoralist area in northern Tanzania, 
before the vaccine was introduced overall calf mortality was 
shown to be 40-80%, with 75% of deaths due to ECF. 
Following adoption of the vaccine, calf mortality rates have 
been dramatically reduced to as low as 2%. Pastoralists also 
report that cattle with the distinctive ECF ear tag attract 
higher prices at markets.  
 
Vaccination also allows the amount of anti-tick spray used to 
be reduced, with environmental and human health benefits. In 
both smallholder dairy and pastoralist areas of northern 
Tanzania, spraying is now often done only once a month 
rather than once a week. Pastoralists also report that when 
their animals are vaccinated they no longer have to avoid 
areas which they know are high ECF risk, enabling them to 
make better use of the grazing resources available to them. 
 
The next step – a new vaccine 
ILRI researchers and their partners are now building on 
decades of research in cattle immunology and the molecular 
biology of the parasite to exploit the very latest advances in 
biotechnology, with the aim of developing a sub-unit vaccine 
– one that is based on carefully chosen protective biological 
molecules rather than live parasites. If ILRI’s research is 
successful, the resulting vaccine will be cheaper, safer and 
much more convenient to use than the current ECF ITM 
vaccine. 
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